Health Care • Medical Specialities
$0.98 ▼ -0.08
(-7.79%)
MKT CAP: $2.9M • VOL: 4.1K
52W L $1 52W H $6
BGLC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.4M | $9.5M | $9.8M |
| YoY Revenue Growth % | -21.9% | -2.7% | — |
| Gross Profit | $1.1M | $1.3M | — |
| Gross Margin % | 14.6% | 13.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$3.0M | -$1.6M | -$2.6M |
| Operating Margin % | -39.9% | -16.5% | -26.5% |
| Net Income (GAAP) | -$3.0M | -$1.6M | -$2.6M |
| EBITDA (Normalized) | -$2.9M | -$1.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.8M | -$2.1M | -$1.8M |
| Capital Expenditures (CapEx) | $37.0K | $227.0K | — |
| Free Cash Flow (FCF) | -$1.9M | -$2.3M | -$1.8M |
| FCF Margin % | -25.3% | -24.4% | -18.6% |
| Return on Invested Capital (ROIC %) | -37.6% | -22.9% | — |
| Cash & Short-Term Equivalents | $2.4M | $2.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.6M | $8.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BGLC.